摘要
目的观察阿德福韦酯(ADV)与拉米夫定(LAM)联合治疗和ADV单药治疗LAM耐药HBeAg(+)慢性乙型肝炎的疗效和安全性。方法LAM耐药HBeAg(+)慢性乙型肝炎患者43例,随机分为A、B两组,A组(24)予以ADV与LAM联合治疗,B组单独用ADV治疗。分别在12、24、36、48周观察HBVDNA转阴率、ALT复常率、HBeAg转阴率及血清学转换率、再次发生病毒学突破率及不良反应等。结果48周时,A、B两组间HBVDNA转阴率、ALT复常率,HBeAg转阴及血清转换率,再次发生病毒学突破率均有统计学意义(P<0.05),A组优于B组;A、B两组均未发现与药物相关的不良反应。结论ADV单药及ADV与LAM联合用于LAM耐药HBeAg(+)患者均有较好疗效;同时ADV与LAM联合治疗效果优于ADV单药治疗,并可明显减少病毒学突破,提高血清学转换率,安全性好。
Objective To investigate the efficacy and safety to HBeAg（＋） chronic hepatitis B（CHB） patients with LAM-R by using adefovior and Lamivudine combination or adefovior monotherapy.Methods 43 HBeAg（＋）patients with LAM-R from May 2005 to October 2007 in our hospital were divided into 2 groups, group Awere treated with lamivudine and adefovior combination therapy; group B were treated with adefovior monotherapy.Undetectable DNA,ALT normalization, HBeAg loss and HBeAg seroconversion, viral rebound again,and side effects were assessed during the following 12,24 36,48 weeks.Results There was significant difference in undetectable DNA, ALT normalization, HBeAg loss and HBeAg seroconversion, viral rebound again between group A and B （P〈0.05）. Conclusion The efficacy of Adefovir and Lamivudine combination therapy is better than that of Adefovir monotherapy in HBeAg （＋） CHB patients,and the combination therapy can reduce viral rebound again,the safety is good.
出处
《江西医药》
CAS
2008年第11期1148-1150,共3页
Jiangxi Medical Journal
关键词
阿德福韦酯
拉米夫定
慢性乙型肝炎
治疗
抗药性
Adefovir dipivoxil
Lamivudine
chronis hepatitisB
therapy
drug resistance
